Q2 2022

Filed Aug 5, 2022 · 10-Q · 36 days after period end · 0001615219-22-000124

Q2 2022 · 10-Q

Revenue

$0.00

−100.0% vs Q2 2021

Net Income

-$4.72M

N/M vs Q2 2021

EPS Diluted

-$2.20

N/M vs Q2 2021

Operating Income-$4,757,967N/M

Operating Cash Flow

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$0.00	$571.39K	$1.24M	$895.78K
Net Income	-$4.72M	-$3.07M	-$1.78M	-$903.65K
EPS Diluted	-$2.20	-$0.07	-$0.13	-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR